MedinCell S.A (MDCLF PINK) stock market data APIs
$6.9672
0(0%)
as of September 15, 2025
Try our APIs with
free plan!
MedinCell S.A Financial Data Overview
Price chart is built with
Anychart
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Prev. Close
6.9672
Open
6.9672
High
6.9672
Low
6.9672
52 wk Range
6.9757-6.976
Market Cap
231 M
Shares Outstanding
33 089 K
Revenue
27 727 K
Beta
1.109
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MedinCell S.A data using free add-ons & libraries
Get MedinCell S.A Fundamental Data
MedinCell S.A Fundamental data includes:
- Net Revenue: 27 727 K
- EBITDA: -10 071 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MedinCell S.A News
New
Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors
MONTPELLIER, France, September 12, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent ...
3 European Growth Companies Insiders Are Investing In
Amidst a backdrop of political instability in France and renewed tariff uncertainties, the European market has experienced a downturn, with major indices such as the STOXX Europe 600 Index seeing nota...
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025
MONTPELLIER, France, July 30, 2025--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information: About UZEDY® 1-Month and 2-Mo...
Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch
MONTPELLIER, France, July 29, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, aCNS-focused...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
